Analys

Oncopeptides (Q3 Initial take): Sequential Growth of 5% - Redeye

{newsItem.title}

Redeye Publicerad: 05 Nov 08:41

Redeye provides its first take on Oncopeptides' Q3 report 2025. Sales grew 5% versus Q2 2025. Operating costs amounted to SEK-67m, with an EBIT of SEK-47m. Overall, the quarter was somewhat below our expectations.

Länk till analysen i sin helhet: https://www.redeye.se/research/1135506/oncopeptides-q3-initial-take-sequential-growth-of-5?utm_source=finwire&utm_medium=RSS

Nyheter om Oncopeptides

Läses av andra just nu

Om aktien Oncopeptides

Senaste nytt